Abstract
Ultraviolet B (UVB) radiation is responsible for the majority of cutaneous damage following both acute and long-term exposure, and is believed to be the most important etiologic agent in human skin cancer. UVB carcinogenesis initially induces an inflammatory response characterized by edema, dermal infiltration of leukocytes, as well as the production and release of prostaglandins, which may be critical to the observed damaging effects of UVB light on skin. Recently, a specific cyclooxygenase-2 (COX-2) inhibitor, Celecoxib, was developed, which inhibits COX-2-induced inflammation without inhibiting the cytoprotective function of cyclooxygenase-1 (COX-1). Studies have demonstrated that oral administration of Celecoxib decreased the incidence of skin and colon tumors. Recently, the process of inflammation has been linked to tumor formation. The present study examined the effects of a topical application of Celecoxib on the acute UVB-induced cutaneous inflammatory response. We show that topical Celecoxib treatment effectively reduced many parameters of UVB-mediated inflammation, including edema, dermal myeloperoxidase activity, neutrophil infiltration,and prostaglandin E2 (PGE2) levels. By inhibiting this inflammatory response, topical Celecoxib treatment could ultimately be effective in preventing tumor development and progression in the skin, which is known to result from long-term UV exposure.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
N. Cascinelli and R. Marchesini, Increasing incidence of cutaneous melanoma, ultraviolet radiation and the clinician, Photochem Photobiol. 50:497 (1989).
R.N. Mitchell and R.S. Cotran, Acute and choursonic inflammation, in:Basic Pathology 6 ’ h editionby V. Kumar, R.S. Cotran and S.L. Robbins, eds., W.B. Saunders Co., Philadelphia (1997).
V.A. Ziboh and J.T. Lord, Activation of phospholipase A2 and increased release of prostaglandin precursor from skin by ultraviolet irradiation, J Invest Dermatol. 70:211 (1978).
J.L. Wallace, Prostaglandins, NSAIDs, and cytoprotection, Gastroenterol Clin North Am. 21:L631 (1992).
H.R. Hershman, Prostaglandin synthase 2. Biochem Biophys Acta. 1299:125 (1996).
G. Furstenberger, M. Gross, and F. Marks, Eicosanoids and multi-stage carcinogenesis in NMRI mouse skin: role of prostaglandin El and F in conversion (first stage of tumor promotion) and promotion (second stage of tumor promotion), Carcinogenesis. 10:91 (1989).
T.T. Jung, N.T. Berlinger and S.K. Juhn, Prostaglandins in squamous cell carcinomas of the head and neck, Laryngoscope. 95:307 (1985).
L.F. Mamet, Aspirin and the potential role of prostaglandins in colon cancer, Cancer Res. 52:5575 (1992).
V. E. Steele, R.C. Moon, et al., Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from the NCA chemoprevention Drug Development Program, J Cell Biol. Suppl. 20:32 (1994).
F.M. Robertson, M.L. Parrett, F.S. Joarder, M.S. Ross, H.M. Abou-Issa, G. Alshafie and R.E. Harris, Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas, Cancer Letters. 122:165 (1998).
S.M. Fischer, H.H. Lo, G.B. Gordon, K. Siebert, G. Kelloff, R.A. Lubet and C.J. Conti, Chemopreventative activity of celecoxib, a specific cyclooxygenase inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis, Molec Carcinogen. 25:231 (1999).
C. Patrono and M.J. Dunn, The clinical significance of inhibition of renal prostaglandin synthesis, Kidney Inst. 32:1 (1987).
B.S. Reddy, C.V. Rao and K. Seibert, Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis, Cancer Res. 56:4566 (1996).
M.L. Parrett, H.M. Abou-Issa, G. Alshafie, M.S. Ross, R.E. Harris and F.M. Robertson, Comparative ability of ibuprofen and N-(4-hydroxyphenyl)retinamide to inhibit development of rat mammary adenocarcinomas associated with differential inhibition of gene expression of cyclooxygenase isoforms, Anti-Cancer Res. 19:5079 (1999).
A.P. Pentland, W. Schoggins, G.A. Scott, K.N.M. Khan and R. Han, Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition, Carcinogenesis. 20:1939 (1999).
T.M. Oberyszyn, K.L. Tober, M.S. Ross and F.M. Robertson, Inhibitory effects of pentoxifylline on ultraviolet B light-induced cutaneous inflammation, Molec Carcinogen. 22:16 (1998).
M.C. Stern, I.B. Gimenez-Conti, I. Budunova, et al., Analysis of two inbred strains of mice derived from the SENCAR stock with different susceptibility to skin tumor progression, Carcinogenesis. 19:125 (1998).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media New York
About this chapter
Cite this chapter
Wilgus, T.A., Parrett, M.L., Ross, M.S., Tober, K.L., Robertson, F.M., Oberyszyn, T.M. (2002). Inhibition of Ultraviolet Light B-Induced Cutaneous Inflammation by A Specific Cyclooxygenase-2 Inhibitor. In: Honn, K.V., Marnett, L.J., Nigam, S., Dennis, E., Serhan, C. (eds) Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury, 5. Advances in Experimental Medicine and Biology, vol 507. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0193-0_14
Download citation
DOI: https://doi.org/10.1007/978-1-4615-0193-0_14
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-4960-0
Online ISBN: 978-1-4615-0193-0
eBook Packages: Springer Book Archive